Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Ningxia Zhongke Biotechnology Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:600165'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3654.23 Med: -15.69 Max: 7.72
Current: -25.68
During the past 13 years, Ningxia Zhongke Biotechnology Co's highest Return-on-Tangible-Equity was 7.72%. The lowest was -3,654.23%. And the median was -15.69%.
SHSE:600165's Return-on-Tangible-Equity is ranked worse than 92.47% of 1568
companies
in the Chemicals industry
Industry Median: 5.785
vs SHSE:600165: -25.68
Ningxia Zhongke Biotechnology Co (SHSE:600165) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ningxia Zhongke Biotechnology Co Return-on-Tangible-Equity Related Terms
Ningxia Zhongke Biotechnology Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningxia Zhongke Biotechnology Co Return-on-Tangible-Equity Chart
SHSE:600165 vs LIN, SHW, ECL: Return-on-Tangible-Equity Comparison
For the Specialty Chemicals subindustry, Ningxia Zhongke Biotechnology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ningxia Zhongke Biotechnology Co Return-on-Tangible-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Ningxia Zhongke Biotechnology Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ningxia Zhongke Biotechnology Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -23.05% mean?
Ningxia Zhongke Biotechnology Co (SHSE:600165) has a Return-on-Tangible-Equity of -23.05% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ningxia Zhongke Biotechnology Co and its competitors. According to the industry distribution chart, Ningxia Zhongke Biotechnology Co ranks #1450 out of 1568 companies in the Chemicals industry, placing it in the top 92.5%.
Is Ningxia Zhongke Biotechnology Co's Return-on-Tangible-Equity too high?
Ningxia Zhongke Biotechnology Co's current Return-on-Tangible-Equity is -23.05%. Based on the distribution chart, Ningxia Zhongke Biotechnology Co ranks #1450 out of 1568 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Ningxia Zhongke Biotechnology Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ningxia Zhongke Biotechnology Co's Return-on-Tangible-Equity compare to LIN and SHW?
According to the Chemicals industry distribution chart, Ningxia Zhongke Biotechnology Co ranks #1450 out of 1568 companies for Return-on-Tangible-Equity. This places Ningxia Zhongke Biotechnology Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 5.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Chemicals company?
The median Return-on-Tangible-Equity among Chemicals companies is 5.79, based on 1,568 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ningxia Zhongke Biotechnology Co and its competitors. For the Chemicals industry, the median Return-on-Tangible-Equity is 5.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningxia Zhongke Biotechnology Co's current Return-on-Tangible-Equity is -23.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningxia Zhongke Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co (SHSE:600165) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥2.77, compared to a current price of ¥2.43 — trading 12.3% below its estimated fair value. The current Return-on-Tangible-Equity is -23.05%. Ningxia Zhongke Biotechnology Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ningxia Zhongke Biotechnology Co (SHSE:600165), the current Return-on-Tangible-Equity is -23.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningxia Zhongke Biotechnology Co (SHSE:600165) Overvalued in 2026?
Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co stock appears to be undervalued.
The current stock price of ¥2.43 is trading 12.3% below its estimated GF Value™ of ¥2.77.
GuruFocus considers Ningxia Zhongke Biotechnology Co to be Modestly Undervalued.
Key valuation signals for SHSE:600165:
Return-on-Tangible-Equity: -23.05%
GF Value™: ¥2.77 vs. price of ¥2.43 (12.3% below fair value)
No single metric tells the full story. See the SHSE:600165 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ningxia Zhongke Biotechnology Co Business Description
Ningxia Zhongke Biotechnology Co Ltd is engaged in the production and sales of activated carbon products, preparation and storage of stem cells, trade and other businesses, as well as lauric acid.
53GF Score
Get the complete analysis for SHSE:600165
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600165 has been successfully added to your 
